Albireo Exits NASH, But Has Best-In-Class IBAT Opportunity

 
• By Joseph Haas
  
Autonomous self driving electric car change the lane and overtakes city vehicle 3d rendering
Exiting NASH, Albireo now will put full focus on pediatric cholestatic diseases
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D